A review of the effects of tibolone on the skeleton

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 941-949

  Devogelaer, Jean Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bone mineral density; Dual energy X ray absorptiometry (DXA); Fractures; Postmenopausal osteoporosis; Quantitative computed tomography; Tibolone

Indexed keywords

ALENDRONIC ACID; ANTIESTROGEN; BASEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CENTCHROMAN; CONJUGATED ESTROGEN; DRUG METABOLITE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTROGEN DERIVATIVE; FLUORIDE ION; FLUORIDE SODIUM; GESTAGEN; IBANDRONIC ACID; IDOXIFENE; LASOFOXIFENE; LIVIFEM; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

BLEEDING; BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL STUDY; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; FRACTURE; HEPATITIS; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MENOPAUSAL SYNDROME; MORBIDITY; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

BONE DENSITY; DRUG THERAPY, COMBINATION; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 1842865611     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.941     Document Type: Review

References (54)

1. ANONYMOUS: Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. (1993) 94:646-650.
2. CUMMINGS SR, MELTON LJ III: Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 359:1761-1767.
3. WORLD HEALTH ORGANIZATION: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. (1994) 843:1-129.
4. DEVOGELAER JP: How do you know who needs prevention or treatment? Baillière's Clin. Rheum. (1997) 11:539-563.
5. MELTON LJ 3rd, CHRISCHILLES EA, COOPER C, LANE AW, RIGGS BL: Perspective. How many women have osteoporosis? J. Bone Miner. Res. (1992) 7:1005-1010.
6. COOPER C: Epidemiology of osteoporosis. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (5th edn). Section VI Metabolic Bone Diseases. Favus MJ (Ed.), American Society for Bone and Mineral Research, Washington DC, (2003) Chap. 49:307-313.
7. NAGANT DE DEUXCHAISNES C, DEVOGELAER JP: Increase in the incidence of hip fractures and of the ratio of trochanteric to cervical hip fractures in Belgium. Calcif. Tissue Int. (1988) 42:201-203.
8. CRANNEY A, GUYATT G, GRIFFITH L et al.: IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. (2002) 23:570-578.
9. NAGANT DE DEUXCHAISNES C, DEVOGELAER JP: Restorative therapy of osteoAorosis. In: 0steoporosis: a guide to diagnosis and treatment. Bröll H, Dambacher MA (Eds). Basel, Karger 18 (1996):207-264.
10. NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
11. MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350:459-468.
12. BJARNASON NH, BJARNASON K, HAARBO J, ROSENQUIST C, CHRIPTIANSEN C: Tibolone: prevention of bone loss in late postmenopausal women. J. Clin. Endocrinol. Metab. (1996) 81:2419-2422.
13. KLOOATERBOER HJ: Tibolone: a steroid with a tissue-specific mode of action. J. Steroid Biochem. (2001) 76:231-238.
14. DE GOOYER ME, DECKERS GH, SCHOONEN WGEJ, VERHEUL HAM, KLOOSTERBOER HJ: Receptor profiling and endocrine interactions of tibolone. Steroids (2003) 68:21-30.
15. ALBEATAZZI P, DI MICCO R, ZANARDI E: Tibolone: a review. Maturitas (1998) 30:295-305.
16. DAVIS SR: The effects of tibolone on mood and libido. Menopause (2002) 9:162-170.
17. CHLEBOWSKI RT, HENDRIX SL, LANGER RD et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA (2003) 289:3243-3253.
18. LI CI, MALONE KE, PORTER PL et al.: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 289:3254-3263.
19. BANKS E, BERAL V, BULL D, REEVES G and the MILLION WOMEN STUDY COLLABORATORS: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 362:419-427.
20. MUECK AO, LIPPERT C, SEEGER H, WALLWIENER D: Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch. Gynecol. Obstet. (2003) 267:139-144.
21. ZANDBERG P, PETERS JLM, DEMACKER M, DE REEDER EG, SMIT MJ, MEULEMAN DG: Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause (2001) 8:96-105.
22. FARISH E, BARNES JF, ROLTON HA, SPOWART K, FLETCHER CD, HART DM: Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas (1995) 20:215-219.
23. HAENGGI W, BERSINGER NA, MUELLER MD, BIRKHAEUSER MH: Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol. Endocrinol. (1999) 13:202-205.
24. EDERVEEN AGH, KLOOSTERBOER HJ: Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J. Bone Miner. Res. (2001) 16:1651-1652.
25. LINDSAY R, HART DM, KRASZEWSKI A: Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J. (1980) 280:1207-1209.
26. GEUSENS P, DEQUEKER J, GIELEN J, SCHOT LPC: Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas (1991) 13:155-162.
27. BJARNASON NH, BJARNASON K, HASSAGER C, CHRISTIANSEN C: The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone (1997) 20:151-155.
28. BERNING B, KUIJK CV, KUIPER JW, COELINGH BENNINK HJT, KICOVIC PM, FAUSER BCJM: Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study. Bone (1996) 19:395-399.
29. STUDD J, ARNALA I, KICOVIC PM, ZAMBLERA D, KRÖGER H, HOLLAND N: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet. Gynecol. (1998) 92:574-579.
30. PAVLOV PW, GINSBURG J, KICOVIC PM, VAN DER SCHAAF DB, PRELEVIC G, COELINGH BENNINK HJT: Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol. Endocrinol. (1999) 13:230-237.
31. GALLAGHER JC, BAYLINK DJ, FREEMAN R, MCCLUNG M: Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies. J. Clin. Endocrinol. Metab. (2001) 86:4717-4726.
32. DEVOGELAER JP, DEPRESSEUX G, LE THI C, NAGANT DE DEUXCHAISNES C: Reproducibility of dual photon absorptiometry on novo type 22A in relation to various procedures and interfering factors. In: Bone mineral measurement by photon absorptiometry. Dequeker J, Geusens P, Wahner HW (Eds), Leuven University Press, Leuven (1988):205-214.
33. LYRITIS GP, KARPATHIOS S, BASDEKIS K et al.: Prevention of postoophorectomy bone loss with tibolone. Maturitas (1995) 22:247-253.
34. BEARDSWORTH SA, KEARNEY CE, PURDIE DW: Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial. Br. J. Obstet. Gynaecol. (1999) 106:678-683.
35. MILNER M, HARRISON RF, GILLIGAN E, KELLY A: Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause (2000) 7:327-333.
36. RYMER J, ROBINSON J, FOGELMAN I: Ten years of treatment with tibolone 2.5 mg daily: Effects on bone loss in postmenopausal women. Climacteric (2002) 5:390-398.
37. PRELEVIC GM, BARTRAM C, WOOD J, OKOLO S, GINSBURG J: Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol. Endocrinol. (1996) 10:413-420.
38. LIPPUNER K, HAENGGI W, BIRKHAEUSER MH, CASEZ JP, JAEGER P: Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J. Bone Miner. Res. (1997) 12:806-812.
39. THIEBAUD D, BIGLER JM, RENTERIA S et al.: A 3-year study of prevention of postmenopausal bone loss: Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric (1998) 1:202-210.
40. CASTELO-BRANCO C, VICENTE JJ, FIGUERAS F et al.: Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas (2000) 34:161-168.
41. ROUX C, PELISSIER C, FECHTENBAUM J, LOISEAU-PERES S, BENHAMOU CL: Randomized, double-masked, 2-year comparision of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos. Int. (2002) 13:241-248.
42. DEVOGELAER JP, NAGANT DE DEUXCHAISNES C: Use of pamidronate in chronic and acute bone loss conditions. Medicina (1997) 57(Suppl. 1):101-108.
43. GREENSPAN SL, EMKEY RD, BONE HG 3rd et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2002) 137:875-883.
44. BERNING B, KUIJK CV, KUIPER JW, COELING H, BENNINK HJT, FAUSER BCJM: Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 year hormone replacement therapy with tibolone. Maturitas (1999) 31:151-159.
45. FELSON DT, ZHANG MPHY, HANNAN MT, KIEL DP, WILSON PWF, ANDERSON JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. (1993) 329:1141-1146.
46. RYMER J, CHAPMAN MG, FOGELMAN I: Effect of tibolone on postmenopausal bone loss. Osteoporos. Int. (1994) 4:314-319.
47. RYMER J, ROBINSON J, FOGELMAN I: Effects of 8 years of treatment wih tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int. (2001) 12:478-483.
48. HUBER J, PALACIOS S, BERGLUND L et al.: Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br. J. Obstet. Gynaecol. (2002) 109:886-893.
49. VALVIDIA I, ORTEGA D: Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin. Drug Invest. (2000) 20:101-107.
50. CHRISTODOULAKOS GE, LAMBRINOUDAKI IV, VOURTSI AD, PANOULIS KP, KELEKIS DA, CREATSAS GC: Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: A prospective study. Menopause (2002) 9:110-116.
51. REGINSTER J-Y, AGNUSDEI D, GENNARI C, KICOVIC PM: Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol. Endocrinol. (1999) 13:361-368.
52. BROOKE-WAVELL K, PRELEVIC GM, BARTRAM C, GINSBURG J: The influence of physical activity on the response of bone mineral density to 5 years tibolone. Maturitas (2000) 35:229-235.
53. DÖREN M, NILSSON J-A, JOHNELL O: Effects of specific postmenopausal hormone therapies on bone mineral density in post-menopausal women: A meta-analysis. Human Reprod. (2003) 18:1737-1746.
54. COMPSTON JE, YAMAGUCHI K, CROUCHER PI, GARRAHAN NJ, LINDSAY PC, SHAW RW: The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone (1995) 16:261-267.